Literature DB >> 20497994

Unveiling the vasodilatory actions and mechanisms of relaxin.

Kirk P Conrad1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20497994      PMCID： PMC3392655          DOI： 10.1161/HYPERTENSIONAHA.109.133926

Source DB:  PubMed          Journal:  Hypertension        ISSN： 0194-911X            Impact factor:   10.190


× No keyword cloud information.
  59 in total

1.  Relaxin is essential for renal vasodilation during pregnancy in conscious rats.

Authors:  J Novak; L A Danielson; L J Kerchner; O D Sherwood; R J Ramirez; P A Moalli; K P Conrad
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

2.  Is the pregnancy hormone relaxin also a vasodilator peptide secreted by the heart?

Authors:  Carol Fisher; Margaret MacLean; Ian Morecroft; Alison Seed; Fiona Johnston; Christopher Hillier; John McMurray
Journal:  Circulation       Date:  2002-07-16       Impact factor: 29.690

3.  Time course and dose response of relaxin-mediated renal vasodilation, hyperfiltration, and changes in plasma osmolality in conscious rats.

Authors:  Lee A Danielson; Kirk P Conrad
Journal:  J Appl Physiol (1985)       Date:  2003-06-20

4.  Myogenic reactivity is reduced in small renal arteries isolated from relaxin-treated rats.

Authors:  Jacqueline Novak; Rolando J J Ramirez; Robin E Gandley; O David Sherwood; Kirk P Conrad
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2002-08       Impact factor: 3.619

5.  The pregnancy hormone relaxin is a player in human heart failure.

Authors:  T Dschietzig; C Richter; C Bartsch; M Laule; F P Armbruster; G Baumann; K Stangl
Journal:  FASEB J       Date:  2001-10       Impact factor: 5.191

6.  Inotropic responses to human gene 2 (B29) relaxin in a rat model of myocardial infarction (MI): effect of pertussis toxin.

Authors:  Andrew R Kompa; Chrishan S Samuel; Roger J Summers
Journal:  Br J Pharmacol       Date:  2002-11       Impact factor: 8.739

7.  Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia.

Authors:  Sharon E Maynard; Jiang-Yong Min; Jaime Merchan; Kee-Hak Lim; Jianyi Li; Susanta Mondal; Towia A Libermann; James P Morgan; Frank W Sellke; Isaac E Stillman; Franklin H Epstein; Vikas P Sukhatme; S Ananth Karumanchi
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

8.  Essential role for vascular gelatinase activity in relaxin-induced renal vasodilation, hyperfiltration, and reduced myogenic reactivity of small arteries.

Authors:  Arundhathi Jeyabalan; Jacqueline Novak; Lee A Danielson; Laurie J Kerchner; Shannon L Opett; Kirk P Conrad
Journal:  Circ Res       Date:  2003-10-30       Impact factor: 17.367

Review 9.  Relaxin: new peptides, receptors and novel actions.

Authors:  Ross A D Bathgate; Chrishan S Samuel; Tanya C D Burazin; Andrew L Gundlach; Geoffrey W Tregear
Journal:  Trends Endocrinol Metab       Date:  2003-07       Impact factor: 12.015

10.  Relaxin, a pregnancy hormone, is a functional endothelin-1 antagonist: attenuation of endothelin-1-mediated vasoconstriction by stimulation of endothelin type-B receptor expression via ERK-1/2 and nuclear factor-kappaB.

Authors:  Thomas Dschietzig; Cornelia Bartsch; Christoph Richter; Michael Laule; Gert Baumann; Karl Stangl
Journal:  Circ Res       Date:  2003-01-10       Impact factor: 17.367
View more
  28 in total

Review 1.  The emerging role of relaxin as a novel therapeutic pathway in the treatment of chronic kidney disease.

Authors:  Jennifer M Sasser
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-07-24       Impact factor: 3.619

2.  Relaxin ameliorates hypertension and increases nitric oxide metabolite excretion in angiotensin II but not N(ω)-nitro-L-arginine methyl ester hypertensive rats.

Authors:  Jennifer M Sasser; Miklos Molnar; Chris Baylis
Journal:  Hypertension       Date:  2011-06-13       Impact factor: 10.190

Review 3.  Vascular actions of relaxin: nitric oxide and beyond.

Authors:  C H Leo; M Jelinic; H H Ng; S A Marshall; J Novak; M Tare; K P Conrad; L J Parry
Journal:  Br J Pharmacol       Date:  2016-09-30       Impact factor: 8.739

4.  Human recombinant relaxin-2 does not attenuate hypertension or renal injury but exacerbates vascular dysfunction in a female mouse model of SLE.

Authors:  Victoria L Wolf; Taylor L Phillips; Erin B Taylor; Jennifer M Sasser; Michael J Ryan
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-05-24       Impact factor: 4.733

5.  Maternal endothelial function, circulating endothelial cells, and endothelial progenitor cells in pregnancies conceived with or without in vitro fertilization.

Authors:  Kirk P Conrad; Melissa Lingis; Larysa Sautina; Shiyu Li; Yueh-Yun Chi; Yingjie Qiu; Mingyue Li; R Stan Williams; Alice Rhoton-Vlasak; Mark S Segal
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2020-04-29       Impact factor: 3.619

6.  GPCRs as potential therapeutic targets in preeclampsia.

Authors:  Jt McGuane; Kp Conrad
Journal:  Drug Discov Today Dis Models       Date:  2012-07-12

7.  Relaxin regulates vascular wall remodeling and passive mechanical properties in mice.

Authors:  Dan O Debrah; Julianna E Debrah; Jamie L Haney; Jonathan T McGuane; Michael S Sacks; Kirk P Conrad; Sanjeev G Shroff
Journal:  J Appl Physiol (1985)       Date:  2011-05-05

8.  Relaxin induces rapid dilation of rodent small renal and human subcutaneous arteries via PI3 kinase and nitric oxide.

Authors:  Jonathan T McGuane; Julianna E Debrah; Laura Sautina; Yagna P R Jarajapu; Jacqueline Novak; J Peter Rubin; Maria B Grant; Mark Segal; Kirk P Conrad
Journal:  Endocrinology       Date:  2011-05-10       Impact factor: 4.736

9.  Serelaxin-mediated signal transduction in human vascular cells: bell-shaped concentration-response curves reflect differential coupling to G proteins.

Authors:  M Sarwar; C S Samuel; R A Bathgate; D R Stewart; R J Summers
Journal:  Br J Pharmacol       Date:  2014-12-01       Impact factor: 8.739

Review 10.  International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides.

Authors:  Michelle L Halls; Ross A D Bathgate; Steve W Sutton; Thomas B Dschietzig; Roger J Summers
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.